CTIS2023-508635-31-00进行中（未招募）1 期
CA209-9DW - A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma - CA209-9DW
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 763
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participants must have a diagnosis of HCC based on histological confirmation, Participants must have an advanced HCC, Participants must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable previously untreated lesion, Child-Pugh score 5 or 6, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
排除标准
- •Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC, Prior liver transplant, Episodes of hepatic encephalopathy (greater than or equal to [>=] Grade 2) within 12 months prior to randomization, Active brain metastases or leptomeningeal metastases
研究者
相似试验
进行中（未招募）
1 期
A Phase 2/3 Study in Adult and Pediatric Participants with SCDSickle Cell DiseaseCTIS2023-508766-14-00Global Blood Therapeutics Inc.229
进行中（未招募）
1 期
A Phase 3 Randomized, Double-Blind, Multicenter Study Comparingthe Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-DayOral Linezolid for the Treatment of Acute Bacterial Skin and SkinStructure InfectionsAcute Bacterial Skin and Skin Structure InfectionsMedDRA version: 12.1Level: LLTClassification code 10040872Term: Skin infectionEUCTR2010-022168-11-HUTrius Therapeutics, Inc.658
进行中（未招募）
不适用
A Phase 3 Randomized, Double-Blind, Multicenter Study Comparingthe Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-DayOral Linezolid for the Treatment of Acute Bacterial Skin and SkinStructure InfectionsAcute Bacterial Skin and Skin Structure InfectionsMedDRA version: 12.1Level: LLTClassification code 10040872Term: Skin infectionEUCTR2010-022168-11-SKTrius Therapeutics, Inc.658
进行中（未招募）
不适用
The purpose of this study is to learn if an experimental antibiotic calledTR-701 FA can safely and effectively treat a acute bacterial skin or skinstructure infection. The experimental antibiotic will be tested against thealready approved antibiotic Linezolid. The sponsor of the study wants toprove, that the new medication isn't inferior regarding efficacy andsafety as compared to the already approved medication Linezolid.EUCTR2010-022168-11-DETrius Therapeutics, Inc.658
进行中（未招募）
不适用
The purpose of this study is to learn if an experimental antibiotic calledTR-701 FA can safely and effectively treat an acute bacterial skin or skinstructure infection. The experimental antibiotic will be tested against thealready approved antibiotic Linezolid adminstered intravenous to oral. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid.EUCTR2011-002860-26-DETrius Therapeutics, Inc.658